A $13 million grant for research into RNA pollution and brain aging

California $13 million grant opens new research into “RNA pollution” in diseases of brain aging

Researchers from the University of California San Diego School of Medicine, the Salk Institute, and Sanford Burnham Prebys have received a four-year, $13 million grant for a project that could change the way Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and other forms of age-related neurodegeneration are studied. The funds are awarded by the California Institute for Regenerative Medicine, a state agency that finances the development of regenerative medicine, stem cells, and gene-directed therapies. The project is titled “Reversing age-dependent neurodegeneration by elimination of RNA pollution” and is focused on investigating disruptions in RNA processing that, according to the team’s working hypothesis, gradually accumulate in neurons throughout life and reduce the resilience of brain cells to disease.

The central idea of the research is that older neurons do not become diseased only because of known late changes, such as the accumulation of protein aggregates in the brain, but also because of earlier molecular errors that disrupt the normal reading and processing of genetic instructions. Researchers describe this process as “RNA pollution”: a set of incorrectly processed, damaged, or misplaced RNA molecules and related disruptions in cellular regulation. According to UC San Diego’s announcement, such damage can accumulate for decades, create chronic stress in neurons, and contribute to the brain’s vulnerability to diseases that most often appear in older age. This is research in an early, discovery phase, so it is not an announcement of a finished therapy, but an attempt to determine more precisely one of the possible mechanisms that turn aging into a biological basis for neurodegenerative diseases.

Why the research is moving away from late disease symptoms

Previous research into neurodegenerative diseases has often focused on changes visible in later stages of disease, for example protein deposits, neuronal degeneration, or inflammatory changes in brain tissue. Such an approach remains important, but it does not always explain why, in some people with genetic risk, the disease develops only after decades of life, nor why age remains one of the most important risk factors for a number of neurodegenerative disorders. Gene Yeo, professor of cellular and molecular medicine at UC San Diego School of Medicine and director of its Center for RNA Technologies and Therapeutics, describes the working assumption that the predisposing mutation alone does not have to be sufficient for disease development until it is joined by age-related accumulation of RNA disruptions.

Such an interpretation does not remove the importance of genetics, environmental factors, or known pathological changes, but places them within the broader framework of cellular aging. If RNA disruptions are shown to truly weaken the ability of neurons to maintain balance, repair damage, and withstand additional stress, the therapeutic goal could shift toward preserving the “youthful” resilience of neurons before irreversible consequences appear. CIRM’s evaluation materials describe the project as a shift from late protein pathology toward earlier dysfunction at the RNA level. Those materials also state that the concept of “RNA pollution” is a new framework for thinking about disease, especially in Alzheimer’s and Parkinson’s disease, while the role of RNA biology in ALS has already been represented more strongly and for longer in the research field.

Induced neurons should retain the biological age of patients

One of the key technical reasons why the project is considered important is the method of creating human disease models. Common procedures in which adult skin cells are returned to the state of induced pluripotent stem cells are useful for many types of research, but they have an important limitation: reprogramming can “rejuvenate” cells and erase part of the biological traces of aging. If the goal is to study changes that have accumulated in neurons throughout life, such a model can miss precisely what researchers are most interested in.

That is why this project will use transdifferentiation, a procedure by which patients’ skin cells are directly converted into induced neurons. According to the description of the research plan, such neurons better retain donors’ age signatures, so they can serve to study the way RNA disruptions appear in cells that carry the biological trace of aging. The team plans to analyze more than 200 cell lines and samples from patients’ biofluids, including cerebrospinal fluid and blood plasma. The goal is to compare patterns of RNA pollution in healthy aging with patterns that appear in neurodegenerative diseases and determine whether there are recognizable signatures that could one day also be used as biomarkers or therapeutic targets.

Mitochondria, cellular energy, and stress responses are also in focus

The project does not observe RNA disruptions in isolation from the rest of cellular biology. Special attention will be directed at mitochondria, organelles responsible for energy production and a range of signaling processes in the cell. According to the research plan, the team will examine how disruptions in cellular energy production can contribute to the accumulation of RNA pollution and how these processes mutually reinforce each other in old neurons. CIRM’s evaluation mentions a model that links the release of mitochondrial double-stranded RNA, activation of stress pathways, and further errors in RNA processing, which could explain why cellular stress in aging becomes a lasting, rather than temporary, response to damage.

Such an approach is important because neurodegenerative diseases rarely arise from a single isolated disorder. Brain aging includes changes in metabolism, inflammation, damage repair, communication between cells, and gene regulation. In this complex system, RNA can be both an indicator and a participant in disruptions: if it is incorrectly processed, incorrectly relocated, or insufficiently removed, the cell can produce wrong protein messages, respond inadequately to stress, or remain trapped in a state of chronic dysfunction. That is precisely why researchers want to map a broader network of changes, not just one final sign of disease.

Robotic drug screening and RNA therapy

After mapping RNA signatures, the project provides for testing a large number of possible therapeutic approaches. Researchers will use advanced robotics to screen thousands of candidates that could reduce RNA pollution and return neurons toward a healthier state. Among the candidates will be small molecules, including drugs already approved by the U.S. Food and Drug Administration for other indications, as well as targeted RNA therapies. Such an approach can accelerate the early phase of research because part of the safety profile is already known for the repurposing of approved drugs, although efficacy in neurodegenerative diseases must be proven separately.

The most promising candidates will not remain only at the level of flat cell cultures. The team plans to test them on more advanced three-dimensional models of human brain tissue, called iSpheroids, and then in animal models as well. CIRM’s materials state that the project includes patient-derived and aged induced neurons, small-molecule screening, and xenotransplantation of human 3D induced spheroids. This aims to reduce the gap between simple laboratory models and the complex biology of the human brain, which is one of the long-standing problems in the development of drugs for neurodegenerative diseases.

Broader research consortium and the role of California funding

The principal investigator of the project is Gene Yeo from UC San Diego, and co-leaders include Douglas Galasko, Jerome Mertens, and Alex Chaim from UC San Diego School of Medicine, Fred “Rusty” Gage from the Salk Institute, and Anne Bang from Sanford Burnham Prebys. The team brings together expertise in RNA biology, neuroscience, disease modeling, stem cells, cellular biology, screening of therapeutic candidates, and advanced human models. According to UC San Diego, the research is one of six CIRM Discovery, or DISC4, awards for California researchers, worth a total of $80 million.

The DISC4 program is intended for large, interdisciplinary projects that seek to accelerate the fundamental understanding of disease and open the way toward new therapeutic strategies, targets, or biomarkers. CIRM states that the maximum amount per individual grant is $13 million, and the longest duration is four years, which matches the funding awarded for the RNA pollution project. On the official CIRM grant page, the project is listed under number DISC4-19291, with a disease focus that includes Alzheimer’s disease, Parkinson’s disease, ALS, and neurological disorders, and the grant status is marked as “Pre-Active”. This means that the project has been approved and financially defined, but implementation is in an administrative or preparatory phase before full activity.

Potential, but also open questions

Regardless of the scientific ambition, the project has clear limitations that the evaluators also recognized. In CIRM’s final comments, the strengths listed include the use of induced neurons that retain traces of aging, broad sampling, a strong team, and the possibility of developing RNA-directed therapies for Alzheimer’s and Parkinson’s disease. Weaknesses mentioned include the difficulties of integrating large data sets and the risk that too many aspects of cellular aging may be attributed to RNA dysfunction, which could make it harder to focus the research. Such remarks are important because they show that this is high-risk but potentially high-impact research, not a routine step toward therapy.

If the hypothesis is confirmed, the consequences could be significant. Successfully recognizing and reducing age-related RNA disruption could open a new group of therapeutic targets in diseases for which existing treatment options are limited and often directed at slowing symptoms, rather than at the fundamental causes of neuronal vulnerability. At the same time, even negative or partial results can provide value if they show more precisely where RNA biology affects brain aging and where other mechanisms are more dominant. In that sense, the project is also important as a research platform: through more than 200 cell lines, patient biofluids, 3D models, and broad drug screening, it can create a data set that will be useful even beyond the initial hypothesis.

What success would mean for the treatment of neurodegenerative diseases

The biggest question remains whether neuronal aging can be slowed or partially redirected early enough to reduce the risk of disease or alleviate its course. In UC San Diego’s announcement, Yeo formulated the goal through the idea of preserving neuronal resilience: if age-conditioned RNA deregulation can be slowed, neurons might be able to remain functionally more resilient even in the presence of genetic triggers of neurodegeneration. This is an attractive, but still unproven, thesis. The path from laboratory screening to therapy for humans is usually long, especially in brain diseases, where candidates often fail in later stages because of safety, insufficient effect, or the inability to transfer a laboratory result to a complex human organism.

Still, the value of this grant lies in the attempt to observe neurodegeneration earlier, more broadly, and closer to the biology of human aging. If researchers succeed in distinguishing which RNA changes accompany healthy aging, which mark the onset of disease, and which can be corrected pharmacologically or through RNA-directed approaches, space will open for more precise diagnostic and therapeutic approaches. For Alzheimer’s disease, Parkinson’s disease, and ALS, this would mean a shift toward strategies that do not wait only for the final signs of neuronal degeneration, but seek to preserve cellular stability before the disease develops into its full clinical form.

Sources:
- UC San Diego Today – announcement about the $13 million grant, the research team, the transdifferentiation method, induced neurons, iSpheroids models, and statements by Gene Yeo and John M. Carethers (link)
- California Institute for Regenerative Medicine – official page of grant DISC4-19291 with the amount, status, project title, and focus on Alzheimer’s disease, Parkinson’s disease, ALS, and neurological disorders (link)
- California Institute for Regenerative Medicine – description of the DISC4 program, expected outcomes, duration, and maximum funding amount per grant (link)
- CIRM – official summaries and evaluation comments for DISC4 Discovery 26.1, including project DISC4-19291, the score, stated strengths, weaknesses, and research goals (link)